Donna Delia Asupan, MD
Internal Medicine · Lakeland, FLNPI 1093162554
Payments from drug & device makers
Across 629 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$2K
- Amgen$1K
- AbbVie$932
- Novo Nordisk$882
- Boehringer Ingelheim$717
- plus $3K from 26 others
What the payments were for
- Food & beverage$11,245100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 125 | $2,296 |
| Lilly USA, LLC | 114 | $2,008 |
| Amgen | 86 | $1,292 |
| AbbVie | 51 | $932 |
| Novo Nordisk | 50 | $882 |
| Boehringer Ingelheim | 37 | $717 |
| Pfizer | 36 | $697 |
| GSK | 17 | $304 |
| Dexcom, Inc. | 12 | $251 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $219 |
| Abbott | 11 | $182 |
| Sanofi-aventis U.S. LLC | 9 | $170 |
| Sumitomo Pharma America, Inc. | 9 | $169 |
| Novartis | 9 | $162 |
| Exact Sciences | 6 | $143 |
| Idorsia Pharmaceuticals US Inc | 6 | $111 |
| Johnson & Johnson | 6 | $101 |
| Kowa Pharmaceuticals America, Inc. | 7 | $101 |
| Axsome Therapeutics, Inc. | 3 | $91 |
| Biohaven Pharmaceuticals, Inc. | 5 | $85 |
| Bayer | 4 | $78 |
| Merck | 3 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$11,254 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 241 | $243,894 |
| OzempicSemaglutide | 184 | $241,606 |
| EliquisApixaban | 189 | $213,034 |
| FarxigaDapagliflozin Propanediol | 125 | $112,188 |
| Repatha SureclickEvolocumab | 85 | $70,888 |
| MounjaroTirzepatide | 63 | $69,010 |
| GemtesaVibegron | 85 | $64,299 |
| TradjentaLinagliptin | 65 | $50,552 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $49,710 |
| XareltoRivaroxaban | 53 | $40,575 |
| JanuviaSitagliptin Phosphate | 29 | $36,671 |
| TrulicityDulaglutide | 29 | $29,694 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $29,383 |
| RybelsusSemaglutide | 22 | $25,502 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $20,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $717 | $294,446306 claims |
| Novo NordiskOzempic, Rybelsus | $882 | $267,108206 claims |
| PfizerEliquis | $697 | $213,034189 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,296 | $137,850164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,008 | $98,70492 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $304 | $70,093103 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $169 | $64,29985 claims |
| MerckJanuvia, Janumet, Belsomra | $43 | $62,62060 claims |
| Johnson & JohnsonXarelto | $101 | $40,57553 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $18,46514 claims |
| NovartisEntresto | $162 | $18,31113 claims |
| AbbVieLinzess | $932 | $16,13212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lakeland
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.